Keyphrases
Chimeric Antigen Receptor T-cell Therapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Large B-cell Lymphoma
100%
Anti-CD19 chimeric Antigen Receptor T Cells
50%
HLA-matched Donor
33%
Treatment Failure
33%
Cumulative Incidence
33%
Lymphoma Patients
33%
Progression-free Survival
33%
Overall Survival
33%
Chimeric Antigen Receptor T Cells (CAR-T)
33%
Cell Treatment
33%
Graft-versus-host Disease (GvHD)
33%
Patient Care
16%
Conditioning Regimen
16%
Transplantation
16%
High Incidence
16%
Confidence Interval
16%
Disease Progression
16%
Multivariable
16%
Progressive Disease
16%
Disease Status
16%
Recurrent Disease
16%
Partial Response
16%
Elevated Lactate
16%
Lactate Dehydrogenase
16%
Complete Response
16%
Salvage Therapy
16%
Duration of Response
16%
Day Range
16%
Relapsed or Refractory
16%
Non-relapse Mortality
16%
High Toxicity
16%
Hepatic Toxicity
16%
Multicenter Observational Study
16%
Sinusoidal Obstruction Syndrome
16%
Transformed Lymphoma
16%
Alternative Donor
16%
Medicine and Dentistry
Hematopoietic Stem Cell
100%
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Large-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell
60%
Cumulative Incidence
40%
Overall Survival
40%
Progression Free Survival
40%
Disease
20%
Recurrent Disease
20%
Observational Study
20%
Progressive Disease
20%
Disease Exacerbation
20%
Lactate Dehydrogenase
20%
Salvage Therapy
20%
Acute Graft Versus Host Disease
20%
Chronic Graft Versus Host Disease
20%
Liver Venoocclusive Disease
20%
Alternative Donor
20%
Immunology and Microbiology
B Cell
100%
Hematopoietic Cell
100%
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
CD19
60%
Chimeric Antigen Receptor T-Cell
60%
Overall Survival
40%
Progression Free Survival
40%
Acute Graft Versus Host Disease
20%
Chronic Graft Versus Host Disease
20%